Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Blood (2019) 134 (Supplement_1): 5276.

https://doi.org/10.1182/blood-2019-130484

Published: 2019

Journal Articles

Comparison of Myeloablative Conditioning Regimes Based on Either Busulfan or Total Body Irradiation in Combination with Fludarabine for Patients with Acute Myeloid Leukemia. a Study on Behalf of the Polish Adult Leukemia Group

Malgorzata Maria Sobczyk Kruszelnicka, MD, Anna Czyz, MD PhD, Anna Lojko-Dankowska, Magdalena Matuszak, Patrycja Mensah-Glanowska, MD PhD, Barbara Nasilowska-Adamska, Agnieszka Piekarska, Tomasz Czerw, Wlodzimierz Mendrek, Jacek Najda, Maria Sadus-Wojciechowska, Jerzy Holowiecki, Sebastian Giebel

Blood (2018) 132 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2018-99-119073

Published: 2018

Journal Articles

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Blood (2018) 132 (Supplement 1): 5375.

https://doi.org/10.1182/blood-2018-99-116610

Published: 2018

Journal Articles

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Lidia Gil, MD PhD, Jan Styczynski, MD, PhD, Agnieszka Piekarska, MD PhD, Beata Jakubas, MD PhD, Katarzyna Drabko, MD PhD, Tomasz Wrobel, prof., Anna Czyz, MD PhD, Anna Lojko-Dankowska, MD PhD, Dominik Dytfeld, MD PhD, Adam Nowicki, MD, Patrycja Mensah-Glanowska, MD PhD, Wanda Knopinska-Posluszny, MD, PhD, Maria Bieniaszewska, MD PhD, Mariusz Wysocki, MD, PhD, Andrzej Hellmann, MD, PhD, Aleksander Skotnicki, Jerzy Kowalczyk, Kazimierz Kuliczkowski, MD PhD, prof., Mieczyslaw Komarnicki, MD PhD

Blood (2011) 118 (21): 3109.

https://doi.org/10.1182/blood.V118.21.3109.3109

Published: 2011

Journal Articles

Clinical Outcome in Patients with AML Exhibiting Poor Mobilization of Progenitor Cells.

Wanda Knopinska-Posluszny, MD, PhD, Michal Taszner, MD, Jan M. Zaucha, MD, PHD, Lucja Kachel, MD, PHD, Anna Czyz, MD, PHD, Lidia Gil, MD, PHD, Jerzy Holowiecki, M. Komarnicki, Andrzej Hellmann

Blood (2006) 108 (11): 5439.

https://doi.org/10.1182/blood.V108.11.5439.5439

Published: 2006

Journal Articles

Delayed Infusion of Allogeneic Stem Cells (72 Hours) Does Not Reduce the Severity of Acute Graft Versus Host Disease in Patients with Chronic Myeloid Leukemia after Myeloablative Conditioning Regimen.

Jan Maciej Zaucha, MD, Lidia Gil, MD, Magdalena Dutka, MD, Anna Czyz, MD, Maria Bieniaszewska, MD, Maria Kozlowska-Skrzypczak, MD, Wanda Knopinska-Posluszny, MD, Andrzej Hellmann, MD, Mieczyslaw Komarnicki, MD

Blood (2005) 106 (11): 5382.

https://doi.org/10.1182/blood.V106.11.5382.5382

Published: 2005

NARROW

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Comparison of Myeloablative Conditioning Regimes Based on Either Busulfan or Total Body Irradiation in Combination with Fludarabine for Patients with Acute Myeloid Leukemia. a Study on Behalf of the Polish Adult Leukemia Group

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Clinical Outcome in Patients with AML Exhibiting Poor Mobilization of Progenitor Cells.

Delayed Infusion of Allogeneic Stem Cells (72 Hours) Does Not Reduce the Severity of Acute Graft Versus Host Disease in Patients with Chronic Myeloid Leukemia after Myeloablative Conditioning Regimen.

Email alerts

ASH Publications

American Society of Hematology

Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group

Comparison of Myeloablative Conditioning Regimes Based on Either Busulfan or Total Body Irradiation in Combination with Fludarabine for Patients with Acute Myeloid Leukemia. a Study on Behalf of the Polish Adult Leukemia Group

Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG)

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Clinical Outcome in Patients with AML Exhibiting Poor Mobilization of Progenitor Cells.

Delayed Infusion of Allogeneic Stem Cells (72 Hours) Does Not Reduce the Severity of Acute Graft Versus Host Disease in Patients with Chronic Myeloid Leukemia after Myeloablative Conditioning Regimen.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only